Related Experiment Video

Updated: Oct 26, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K

Current therapeutics against HCV

Chayan Bhattacharjee1, Maitri Singh1, Debisukti Das1

  • 1Department of Life Science, Presidency University, 86/1 College Street, Kolkata, 700073 India.

Virusdisease
|July 26, 2021
PubMed

Insights

Hepatitis C virus (HCV) causes severe liver disease. This review details HCV

Area of Science:

  • Virology
  • Hepatology
  • Immunology

Background:

  • Hepatitis C virus (HCV), a Flaviviridae family member, causes significant global liver disease, including cirrhosis and hepatocellular carcinoma.
  • Despite existing treatments, HCV's genetic diversity limits therapeutic effectiveness across all genotypes.
  • Understanding HCV's life cycle and immune evasion is crucial for developing better therapies.

Purpose of the Study:

  • To review the Hepatitis C virus life cycle and immunogenic potential.
  • To explore mechanisms of HCV-induced signaling interference.
  • To provide a comprehensive overview of current anti-HCV therapeutics, including Direct Acting Antivirals (DAA) and Host Targeting Agents (HTA).

Main Methods:

  • Literature review of HCV pathogenesis and treatment strategies.
  • Analysis of viral interference with host signaling pathways.
  • Synthesis of information on DAA and HTA mechanisms, scope, and limitations.

Main Results:

  • HCV exhibits complex life cycle and immune evasion strategies.
  • Various signaling pathways are targeted by HCV for replication and persistence.
  • Current DAAs and HTAs offer treatment options but have limitations.

Conclusions:

  • Effective control of Hepatitis C virus requires understanding its intricate life cycle and immune interactions.
  • Direct Acting Antivirals and Host Targeting Agents represent significant advancements but necessitate further research to overcome limitations.
  • Comprehensive knowledge of HCV pathogenesis and therapeutics is vital for global health strategies against this virus.

Keywords:
DAAHCVHTAsTherapeutics

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.4K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
37
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
32
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.0K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
38